Aggressive chemo schedule put to the test in brain cancer trial
NCT ID NCT03663725
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 40 times
Summary
This phase 3 trial tests whether giving the chemotherapy drug temozolomide earlier and for a longer time can help adults with glioblastoma live longer. About 486 participants will receive either the standard treatment or an intensified version that starts chemo within two weeks of surgery and continues until the cancer progresses or side effects become too severe. The study aims to see if this more aggressive approach improves overall survival compared to the usual six-cycle regimen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHP La Pitié Salpêtrière
Paris, 75013, France
-
CH René Dubos
Pontoise, 95300, France
-
CHRU Nancy
Nancy, 54000, France
-
CHRU Tours
Tours, 37044, France
-
CHU Grenoble Alpes
Grenoble, 38043, France
-
CHU La Timone
Marseille, 13385, France
-
CHU de Limoges
Limoges, 87042, France
-
CHU de Nice - Hôpital de Cimiez
Nice, 06000, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Hospitalier d'Amiens
Amiens, 80054, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69673, France
-
Centre Paul Strauss
Strasbourg, 67065, France
-
Hôpitaux Civils de Colmar
Colmar, 68024, France
-
ICM Val d'Aurelle
Montpellier, 34298, France
-
Institut Cancérologie Loire
Saint-Priest-en-Jarez, 42270, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide (chemotherapy)
What this could lead to
If successful, this could show that starting chemotherapy earlier and continuing it longer helps people with glioblastoma live longer.
What could go wrong
This is a phase 3 trial, but glioblastoma is very aggressive and hard to treat. The intensified regimen may cause more side effects without improving survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.